

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May, 2016

Commission File Number: 001-35892

GW PHARMACEUTICALS PLC

(Translation of registrant's name into English)

Sovereign House
Vision Park
Histon
Cambridge CB24 9BZ
United Kingdom
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

Other Events

On May 11, 2016 and on May 13, 2016, GW Pharmaceuticals plc (the “Company”) issued notifications of interests of directors and connected persons through the Regulatory News Service (RNS) of the London Stock Exchange’s AIM market. The RNS’s are attached as Exhibit 99.1 and Exhibit 99.2 hereto and are incorporated by reference herein.

The information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

Exhibits

99.1 Regulatory News Service Announcement dated May 11, 2016

99.2 Regulatory News Service Announcement dated May 13, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GW Pharmaceuticals plc

By: /s/ Adam George

Name: Adam George

Title: Chief Financial Officer

Date: May 13, 2016

GW Pharmaceuticals PLC Director/PDMR Shareholding

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

Cambridge, UK, 11 May 2016: GW Pharmaceuticals (AIM: GWP, NASDAQ:GWPH) hereby provides notification that the Company has today been notified that on 10 May 2016 Thomas Lynch, a non-executive Director of the Company, sold 50,000 0.1 pence Ordinary shares, representing less than 0.1% of shares in issue, at an average price of £4.41 per ordinary share.

Following this transaction Mr Lynch's retained beneficial interest in the 0.1 pence Ordinary shares of GW Pharmaceuticals plc is 2,074 shares.

For further information, please contact:

GW Pharmaceuticals PLC
Adam George, Company Secretary +44 (0)1980 557 000

Peel Hunt LLP (Nominated Adviser)
James Steel/Oliver Jackson +44 (0) 20 7418 8900

GW Pharmaceuticals PLC Director/PDMR Shareholding

13 May 2016

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

Cambridge, UK, 13 May 2016: GW Pharmaceuticals (AIM: GWP, NASDAQ:GWPH) hereby provides notification that the Company was notified on 12 May 2016 of the following series of transactions in the Ordinary 0.1 pence shares of GW Pharmaceuticals PLC.

On 12 May 2016 Dr Geoffrey Guy, a Director of the Company, gifted 200,000 ordinary shares to each of two close family members. Each gift represents less than 0.1% of shares in issue. The gifts took place when the market price was 437 pence per share. As one of these family members is a minor, 200,000 of the gifted shares continue to be included within the calculation of Dr Guy's total beneficial interest.

These transfers follow the sale, by the minor family member, of 300,000 Ordinary shares, representing 0.11% of shares in issue. This sale of these shares completed on 11 May 2016, achieving an average price of 444 pence per Ordinary share.

Following these transactions Dr Guy's total retained beneficial interest in the Ordinary 0.1 pence shares of GW Pharmaceuticals plc is 13,797,852 shares equating to 5.25% of shares in issue.

For further information, please contact:

GW Pharmaceuticals PLC +44 (0)1980 557 000
Adam George, Company Secretary

Peel Hunt LLP (Nominated Adviser) +44 (0) 20 7418 8900
James Steel/Oliver Jackson
